Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • COVID-19
    • COVID-19 Update
    • Evaluate Vantage COVID-19 Report
    • COVID-19 Stories from Evaluate Vantage
    • Evaluate’s Business Continuity Plan
  • What We Do
    • Commercial Intelligence
    • Products
      • EvaluatePharma
      • Evaluate Omnium
      • Japan Drug Forecasts
      • European Drug Forecasts
      • Epi Analyzer
    • Evaluate Custom Solutions
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Data Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
  • How We Can Help You
    • Pharma and Biotech
    • Medtech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
    • Careers
      • Current Vacancies
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Data Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

National Cancer Institute (NCI; USA)

Thumbnail
December 07, 2020

Ash 2020 – US academics target the Car-T relapse problem

Thumbnail
November 27, 2020

Danyelza validates a flotation and an anticancer mechanism

Article image
Vantage logo
May 28, 2020

Asco 2020 – Keytruda a “new standard” in biomarker-driven cancer

The Merck & Co drug looks to extend its position in a biomarker-defined colorectal cancer niche, but is it too early to declare victory?

Article image
Vantage logo
August 28, 2019

Immatics and Adaptimmune show that T-cell receptor deals aren't dead

Article image
Vantage logo
August 09, 2019

Upcoming events – United seeks a Distinct hit, and Biogen nears a rare catalyst

A low-key lung cancer readout approaches for United Therapeutics’ Unituxin, while Biogen hopes to buck the tau trend.

Article image
Vantage logo
June 12, 2019

Ziopharm stakes its reputation on personalised cell therapy

Article image
Vantage logo
April 01, 2019

AACR 2019 – Entinostat turns Syndax’s frown upside down

After two checkpoint combo trials flopped last month Syndax celebrates an unexpected win in a third.

Article image
Vantage logo
March 31, 2019

AACR 2019 – Baylor sets the benchmark for Bellicum

A Baylor College study suggests to investors what Bellicum’s upcoming first-in-human trial of BPX-603 will have to match.

Article image
Vantage logo
March 19, 2019

Celyad spells out its off-the-shelf ambitions

Article image
Vantage logo
March 14, 2019

Bellicum pins its next cell therapy hope on Her2

Article image
Vantage logo
February 26, 2019

A rare pancreatic cancer success, courtesy of a resurgent Lynparza

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

December 10, 2020

Evaluate Vantage 2021 Preview

July 29, 2020

Evaluate Vantage Pharma, Biotech & Medtech Half-Year Review 2020

View more...

Editor's Picks

Vantage logo
December 10, 2020

What the coming year might hold for biopharma

Vantage logo
December 11, 2020

Covid-19 vaccine developers remind the world that setbacks happen

Vantage logo
December 09, 2020

Astrazeneca’s vaccine looks increasingly like an also-ran

Vantage logo
November 09, 2020

Pfizer and Biontech snatch first Covid vaccine victory

Vantage logo
December 01, 2020

The promise and the perils of antigen testing

Open modal

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)80-1164-4754

Footer menu

  • Terms and Conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2020 Evaluate Ltd.